Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTSO Cytosorbents	$1.16 +1.8%	$1.07	$0.71 ▼ $1.61	$72.80M	1.19	324,927 shs	39,034 shs
HYBT Heyu Biological Technology	$0.20	$0.09	$0.00 ▼ $3.40	$20.65M	-17.74	5,371 shs	N/A
NTRB Nutriband	$6.57 +4.3%	$7.83	$3.72 ▼ $11.78	$73.26M	1.13	199,395 shs	38,245 shs
VANI Vivani Medical	$1.25 -1.6%	$1.34	$0.91 ▼ $1.80	$74.05M	2.99	157,272 shs	96,875 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTSO Cytosorbents	0.00%	+16.00%	+12.62%	+36.45%	+11.54%
HYBT Heyu Biological Technology	0.00%	+99,900.00%	+45.99%	-1.23%	-20.00%
NTRB Nutriband	0.00%	-8.37%	-18.99%	+15.06%	+16.90%
VANI Vivani Medical	0.00%	-9.42%	-19.35%	+16.82%	-2.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTSO Cytosorbents	2.1496 of 5 stars	3.3	3.0	0.0	0.0	2.8	0.0	0.6
HYBT Heyu Biological Technology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NTRB Nutriband	3.293 of 5 stars	3.5	5.0	0.0	0.0	2.5	1.7	0.6
VANI Vivani Medical	2.1757 of 5 stars	3.5	3.0	0.0	0.0	1.7	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTSO Cytosorbents	2.50	Moderate Buy	$5.50	374.14% Upside
HYBT Heyu Biological Technology	0.00	N/A	N/A	N/A
NTRB Nutriband	3.00	Buy	$13.00	97.87% Upside
VANI Vivani Medical	3.00	Buy	$4.00	220.00% Upside

Current Analyst Ratings Breakdown

Latest HYBT, VANI, NTRB, and CTSO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	CTSO Cytosorbents	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/21/2025	CTSO Cytosorbents	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/25/2025	CTSO Cytosorbents	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/19/2025	VANI Vivani Medical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTSO Cytosorbents	$36.11M	2.02	N/A	N/A	$0.20 per share	5.80
HYBT Heyu Biological Technology	$80K	258.12	N/A	N/A	$0.38 per share	0.53
NTRB Nutriband	$2.14M	34.23	N/A	N/A	$0.58 per share	11.33
VANI Vivani Medical	N/A	N/A	N/A	N/A	$0.30 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTSO Cytosorbents	-$20.72M	-$0.17	N/A	N/A	N/A	-25.58%	-111.97%	-29.00%	11/6/2025 (Estimated)
HYBT Heyu Biological Technology	-$270K	N/A	0.00	∞	N/A	-453.55%	-6.43%	-4.43%	N/A
NTRB Nutriband	-$10.48M	-$0.90	N/A	N/A	N/A	-415.93%	-68.25%	-60.40%	9/2/2025 (Estimated)
VANI Vivani Medical	-$23.49M	-$0.45	N/A	N/A	N/A	N/A	-194.66%	-68.64%	N/A

Latest HYBT, VANI, NTRB, and CTSO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2025	N/A	NTRB Nutriband	-$0.17	N/A	N/A	N/A	$0.71 million	N/A
8/13/2025	Q2 2025	VANI Vivani Medical	-$0.10	-$0.12	-$0.02	-$0.12	N/A	N/A
8/7/2025	Q2 2025	CTSO Cytosorbents	-$0.07	-$0.05	+$0.02	$0.03	$9.79 million	$9.62 million
5/30/2025	Q1 2026	NTRB Nutriband	-$0.13	-$0.12	+$0.01	-$0.12	$0.71 million	$0.67 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTSO Cytosorbents	N/A	N/A	N/A	N/A	N/A
HYBT Heyu Biological Technology	N/A	N/A	N/A	N/A	N/A
NTRB Nutriband	N/A	N/A	N/A	N/A	N/A
VANI Vivani Medical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTSO Cytosorbents	1.24	2.34	2.30
HYBT Heyu Biological Technology	N/A	0.35	0.34
NTRB Nutriband	0.01	3.71	3.48
VANI Vivani Medical	N/A	1.30	2.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTSO Cytosorbents	32.87%
HYBT Heyu Biological Technology	N/A
NTRB Nutriband	19.70%
VANI Vivani Medical	6.78%

Insider Ownership

Company	Insider Ownership
CTSO Cytosorbents	7.30%
HYBT Heyu Biological Technology	89.24%
NTRB Nutriband	54.09%
VANI Vivani Medical	46.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTSO Cytosorbents	220	62.76 million	58.62 million	Optionable
HYBT Heyu Biological Technology	6	103.25 million	11.11 million	Not Optionable
NTRB Nutriband	10	11.15 million	5.12 million	Not Optionable
VANI Vivani Medical	20	59.24 million	31.76 million	Optionable

HYBT, VANI, NTRB, and CTSO Headlines

Recent News About These Companies

Vivani Medical (NASDAQ:VANI) Stock Price Down 0.8% After Earnings Miss

August 15 at 12:10 AM | marketbeat.com

Vivani Medical (NASDAQ:VANI) Announces Quarterly Earnings Results

August 15 at 11:59 PM | marketbeat.com

Vivani closes $10M financing, advances GLP-1 implant

August 14, 2025 | drugdeliverybusiness.comD

Vivani Medical, Inc.: Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results

August 14, 2025 | finanznachrichten.de

Vivani Medical (NASDAQ:VANI) Stock Price Down 0.8% Following Weak Earnings

August 14, 2025 | americanbankingnews.com

Vivani Medical Reports Q2 2025 Results and $10M Financing

August 13, 2025 | tipranks.com

Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second ...

August 13, 2025 | bakersfield.comB

Vivani Medical Secures $10M Through Share Purchase Agreement

August 13, 2025 | msn.com

Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results

August 13, 2025 | globenewswire.com

Vivani Medical (VANI) to Release Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Vivani Medical, Inc. (NASDAQ:VANI) Sees Large Growth in Short Interest

August 2, 2025 | marketbeat.com

Vivani Medical (NASDAQ:VANI) Shares Up 0.6% - Here's What Happened

July 23, 2025 | marketbeat.com

3 Penny Stocks With Market Caps Over $30M To Consider

July 16, 2025 | finance.yahoo.com

Vivani Medical Insiders Added US$5.29m Of Stock To Their Holdings

June 30, 2025 | uk.finance.yahoo.com

Vivani Medical shareholders elect board and approve key proposals at annual meeting - Investing.com

June 27, 2025 | investing.com

Vivani Medical Appoints Anthony Baldor as Chief Financial Officer

June 11, 2025 | manilatimes.netM

Vivani Medical to Present at the 2025 BIO International Convention

June 11, 2025 | finance.yahoo.com

Vivani Stock Gains After Announcing Spin-Off Plans for Cortigent Unit

June 2, 2025 | zacks.com

Companies To Watch: Vivani Medical

May 30, 2025 | lifescienceleader.comL

Vivani files with SEC to spin off neurostim business, focus on drug delivery implants

May 29, 2025 | massdevice.com

Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders

May 29, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYBT, VANI, NTRB, and CTSO Company Descriptions

Cytosorbents NASDAQ:CTSO

$1.16 +0.02 (+1.75%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.11 -0.05 (-4.66%)

As of 08/15/2025 07:59 PM Eastern

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Heyu Biological Technology OTCMKTS:HYBT

$0.20 0.00 (0.00%)

As of 08/15/2025

Hong Chang Biotechnologies (HK) Limited was incorporated in 2023 and is based in Kowloon, Hong Kong. Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Zengqiang Investment Limited. As of September 4, 2023, Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Heyu Biological Technology Corporation.

Nutriband NASDAQ:NTRB

$6.57 +0.27 (+4.29%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$6.49 -0.08 (-1.28%)

As of 08/15/2025 04:24 PM Eastern

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Vivani Medical NASDAQ:VANI

$1.25 -0.02 (-1.57%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.26 +0.01 (+0.80%)

As of 08/15/2025 07:15 PM Eastern

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time